{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:46Z","timestamp":1792718326447,"version":"4.5.0"},"reference-count":58,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>JAK inhibitor therapies are effective treatment options for immune\u2010mediated inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism (VTE) risk warnings from licensing authorities. We undertook this study to evaluate the VTE risk of JAK inhibitors in patients with IMIDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic searches of Medline and Embase databases from inception to September 30, 2020 were conducted. Phase II and phase III double\u2010blind, randomized controlled trials (RCTs) of JAK inhibitors at licensed doses were included in our analyses. RCTs with no placebo arm, long\u2010term extension studies, post hoc analyses, and pooled analyses were excluded. Three researchers independently extracted data on exposure to JAK inhibitors or placebo and VTE events (e.g., pulmonary embolism [PE] and deep vein thrombosis [DVT]) and assessed study quality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 42 studies were included, from an initial search that yielded 619. There were 6,542 JAK inhibitor patient exposure years (PEYs) compared to 1,578 placebo PEYs. There were 15 VTE events in the JAK inhibitor group and 4 in the placebo group. The pooled incidence rate ratios (IRRs) of VTE, PE, and DVT in patients receiving JAK inhibitors were 0.68 (95% confidence interval [95% CI] 0.36\u20131.29), 0.44 (95% CI 0.28\u20130.70), and 0.59 (95% CI 0.31\u20131.15), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta\u2010analysis of RCT data defines the VTE risk with JAK inhibitors as a class in IMID patients. The pooled IRRs do not provide evidence that support the current warnings of VTE risk for JAK inhibitors. These findings will aid continued development of clinical guidelines for the use of JAK inhibitors in IMIDs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.41580","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T02:29:17Z","timestamp":1605061757000},"page":"779-788","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Venous Thromboembolism Risk With JAK Inhibitors: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5211","authenticated-orcid":false,"given":"Mark","family":"Yates","sequence":"first","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mootoo","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-0463","authenticated-orcid":false,"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanketh","family":"Rampes","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishit","family":"Patel","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumera","family":"Qureshi","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Cope","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Galloway","sequence":"additional","affiliation":[{"name":"King\u2019s College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104392"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1153"},{"key":"e_1_2_6_4_1","unstructured":"Olumiant (baricitinib) prescribing information.Indianapolis (IN):Lilly;2018. URL:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf."},{"key":"e_1_2_6_5_1","unstructured":"US Food and Drug Administration.FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz Xeljanz XR). August 2019. URL:https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010approves\u2010boxed\u2010warning\u2010about\u2010increased\u2010risk\u2010blood\u2010clots\u2010and\u2010death\u2010higher\u2010dose\u2010arthritis\u2010and."},{"key":"e_1_2_6_6_1","unstructured":"European Medicines Agency.EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. November 2019. URL:https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010confirms\u2010xeljanz\u2010beused\u2010caution\u2010patients\u2010high\u2010risk\u2010blood\u2010clots#:~:text=EMA%20has%20concluded%20that%20Xeljanz high%20risk%20of%20blood%20clots."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0651-5"},{"key":"e_1_2_6_8_1","first-page":"171","article-title":"Autoimmune diseases and venous thromboembolism: a review of the literature","volume":"2","author":"Z\u00f6ller B","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-06943-9"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/annrheumdis-2017-eular.1325","article-title":"FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis","volume":"76","author":"Kremer J","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_11_1","unstructured":"HigginsJP SavovicJ PageMJ SterneJA on behalf ofthe RoB2 Development Group.Revised Cochrane risk\u2010of\u2010bias tool for randomized trials (RoB 2). URL:https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob\u20102\u20100\u2010tool\/current\u2010version\u2010of\u2010rob\u20102. August 2019."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312735"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40803"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.05.004"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1318"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150613"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.030"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa084"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_2_6_52_1","unstructured":"US Food and Drug Administration. FDA briefing information for the April 23 2018 meeting of the Arthritis Advisory Committee.URL:https:\/\/www.fda.gov\/media\/112372\/download."},{"key":"e_1_2_6_53_1","unstructured":"Pfizer sponsor. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. ClinicalTrials.gov identifier:NCT02092467; 2020."},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.153536"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000446"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.1.23.bloodjournal86123"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001392"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.122"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:58:35Z","timestamp":1759928315000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/art.41580"],"URL":"https:\/\/doi.org\/10.1002\/art.41580","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"2020-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}